A Phase 3 interventional study of atorvastatin of dose level 1 and atorvastatin of dose level 2 in Kawasaki Disease and Coronary Artery Abnormalities, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Children's Hospital of Fudan University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University — 5 open to participants now, 5 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · Children's Hospital of Fudan University.
Among the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, this one is one of 2 that started in 2026, is one of 4 in phase 3, and was the 10th registered.
62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.
Browse Mucocutaneous Lymph Node Syndrome studies →5 of the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Children's Hospital of Fudan University · Sites in China
Ages 1 mo–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Children's Hospital of Fudan University · Sites in China
Ages 29 days–17 yrs
By country, each count listing its studies:
Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 5 · Phase 4 2
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 45 across 33 interventional studies indexed under Mucocutaneous Lymph Node Syndrome.
Median enrollment 90 across the 7 interventional studies, 1,231 across the 4 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
3 of the studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530640Phase 3Children's Hospital of Fudan UniversityStatins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities | 2027-08-31 |
| NCT07686770Phase 3Children's Hospital of Fudan UniversityEfficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease | 2027-09-01 |
| NCT05643651Children's Hospital of Fudan UniversityRivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?
Kawasaki disease (KD) is acute self-limited vasculitis and occurs almost exclusively in childhood. It predominantly affects medium-sized arteries, most commonly coronary arteries. Although the use of intravenous immunoglobulin (IVIG) has obviously decreased the incidence of coronary arteries abnormalities (CAA), still a part of KD children occurs CAA, even medium, large or giant CA aneurysms. Coronary aneurysms can develop thrombus and arterial stenosis, which may cause severe cardiac events. Now KD has been the main cause of acquired heart disease in children in most areas of China mainland.
Studies have found that during the acute phase of KD, necrotizing arteritis occurs in coronary arteries. Oxidative stress, immune activation, and cellular infiltration of the vessel wall associated with secretion of proinflammatory cytokines, elastases, and matrix metalloproteinases (MMPs) are related to formation of coronary aneurysms. In addition, long-term KD vasculopathy appears ongoing vascular chronic inflammation and oxidative stress. Endothelial dysfunction, increased stiffness, and intima-media thickening have been noted in affected coronary arteries.
Statins, a hydroxymethylglutaryl coenzyme-A reductase inhibitors, has been widely used in adults for years not only for its reducing plasma cholesterol but also for its beneficial pleiotropic effects, including inflammation modulation, oxidative stress, endothelial function and angiogenesis, antithrombotic and antiplatelet effects. In recent years, statins have been considered to be used in KD children with coronary aneurysms. Several studies have shown reductions in high-sensitivity CRP, improved endothelial function and safety in such KD children treated with statins. The 2017 American Heart Association (AHA) scientific statement on KD has suggested that empirical treatment with low-dose statin may be considered for KD patients with past or current aneurysms, regardless of age or sex. The investigators have also conducted a follow-up study of atorvastatin used in long-term treatment of KD children with severe CAA. The results showed that long-term atorvastatin treatment was safe in Chinese KD children with CAA, but its dose was significantly lower than those been reported by previous studies abroad.
Based on the effects of statins on inhibition of MMP secretion and myofibroblast transformation which may anticipate the formation of CAA in acute KD, statins have been tried to be used in acute KD children with CAA. However, the relevant clinical data is very rare.Is atorvastatin safe in Chinese children of acute KD? Can atorvastatin actually contribute to control the acute inflammation of KD and improve CAA? The goal of this study is to learn about the safety and effects of atorvastatin in treatment of Chinese KD children complicated with CAA in acute phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atorvastatin of dose level 1 (0.15 mg/kg/day) for 6 weeks on the basis of conventional therapy.
Drug: atorvastatin of dose level 1
Participants will receive atorvastatin of dose level 2 (0.25 mg/kg/day) for 6 weeks on the basis of conventional therapy.
Drug: atorvastatin of dose level 2
Participants will receive atorvastatin of dose level 3 (0.4 mg/kg/day) for 6 weeks on the basis of conventional therapy.
Drug: atorvastatin of dose level 3
Participants will only receive conventional therapy.
The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).
The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).
The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).
Incidence of statin-associated side effects in Chinese acute KD children with CAA
Safety evaluation of atorvastatin in acute KD children, referring to the incidence of statin-associated side effects (SASE). SASE include statin-associated clinical adverse events, elevated transaminase, creatine kinase, blood glucose and hypocholesterolemia.
Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin
Change of levels of high-sensitivity C reactive protein (sCRP)
Changes of levels of high-sensitivity C reactive protein (sCRP) which reflex the acute KD inflammation
Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin
Change of levels of serum amyloid A(SAA)
Change of levels of serum amyloid A(SAA) which reflex the acute KD inflammation
Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin
Change of levels of interleukin-6 (IL-6)
Change of levels of interleukin-6 (IL-6) which reflex the acute KD inflammation
Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin
Change of levels of NT-proBNP
Change of levels of NT-proBNP which reflex the acute KD inflammation
Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin
Change of levels of albumin
Change of levels of albumin which reflex the acute KD inflammation
Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin
Changes of sizes of involved coronary arteries measured by echocardiography
Changes of diameters of involved coronary artery aneurysms
Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin
Changes of diameter-Z score of involved coronary arteries measured by echocardiography
Changes of Z score of involved coronary artery aneurysms diameters
Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin
Changes of degrees of other echocardiographic findings
Changes of degrees of other echocardiographic findings which reflex the acute KD inflammation, including mitral regurgitation and pericardial effusion
Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mucocutaneous Lymph Node Syndrome →
Children's Hospital of Fudan University →